Federal Register Notice: FDA has determined the regulatory review period for Prevnar-13 is 2,102 days for the extending a patent which claims the human biological product. Prevnar is indicated for active immunization for preventing invasive disease caused by Streptococcus pneumoniae, and for preventing otitis media caused by S. pneumoniae. To view this notice, click here.
